Program
Anti-TREM2 Monoclonal Antibody EOS006215
Its studies are mostly in Neoplasms, led by iTeos Belgium.
Furthest: phase 1, since Mar 10, 20251 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| iTeos Belgium | 10 open or running | phase 1since Mar 10, 2025 | Mar 10, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 10, 2025First study: phase 1 study in NeoplasmsFirst studyNCT06877533 · 3 enrolled · United States
TargetBeta
TREM2 →read by rule
“A human monoclonal antibody targeting triggering receptor expressed on myeloid cells 2 (TREM2; TREM-2), ”NCIt, by rule
Other programs on TREM2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| SAR448851 | Sanofi | phase 2 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06877533Neoplasms · United States | 1 | Terminated | Jul 10, 2025 | 3 |
How it is read
Names in the registry
- “EOS006215”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.